NHS National Generics Pharmaceuticals - Dasatinib and Paliperidone Injection

Invitation to offer for NHS National Generic Pharmaceuticals - Dasatinib and Paliperidone Injection

Offer reference number: CM/PHG/22/5694 FIND A TENDER (FTS) - 2023/S 000-001392 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 21 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement:

CM/PHG/22/5694/00 - Dasatinib CESW 01/05/2023 - 30/04/2024 - (12 Months) LSNE 01/05/2023 - 30/04/2024 - (12 Months) NWLN 01/05/2023 - 30/04/2024 - (12 Months)

CM/PHG/22/5694/01 - Paliperidone Injection: LSNE 01/05/2023 - 31/05/2024 (13 Months) NWLN 01/05/2023 - 31/01/2025 (21 months)